proline rich acidic protein 1Genealiases: PRO1195 · UPA
Q-omics provides the consensus-scored PRAP1 profile across patient tissues and cancer cell-line models. PRAP1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRAP1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PRAP1 RNA expression shows 14,746 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KICH, and TGCT as cancer lineages where PRAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAP1 survival associations across molecular data types. PRAP1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAP1 RNA expression–survival associations across cancer types. High PRAP1 expression shows unfavorable associations in ACC, UCS and UCEC, but favorable associations in KIRP, CESC and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRAP1 RNA expression.
This table summarizes PRAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PRAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAP1 shows lower tumor expression in KICH, KIRP, BRCA and CHOL and higher tumor expression in HNSC and LUSC. The KICH box plot shows higher PRAP1 RNA expression in normal versus tumor tissue (log2 FC = −5.056, t-test p < 0.001).
This table shows molecular features associated with PRAP1 in patient tissues and cancer cell lines. In patient samples, PRAP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
